2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
2seventy bio (Nasdaq: TSVT) announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. The company's management team will engage in a fireside chat, which will be webcast live on the company's website. Replays will be available for 30 days following the event.
2seventy bio is known for developing the first FDA-approved CAR T cell therapy for multiple myeloma. The company's name reflects its mission to work at maximum speed (270 miles per hour) to give cancer patients more time. 2seventy bio focuses on understanding the human body's immune response to tumor cells and translating cell therapies into practice.
2seventy bio (Nasdaq: TSVT) ha annunciato la sua partecipazione alla 22ª Conferenza Globale sulla Salute di Morgan Stanley il 6 settembre 2024 alle 12:20 p.m. ET a New York. Il team di gestione dell'azienda parteciperà a una conversazione informale, che sarà trasmessa in diretta sul sito web dell'azienda. Le registrazioni saranno disponibili per 30 giorni dopo l'evento.
2seventy bio è conosciuta per aver sviluppato la prima terapia CAR T cell FDA approvata per il mieloma multiplo. Il nome dell'azienda riflette la sua missione di lavorare a velocità massima (270 miglia orarie) per dare più tempo ai pazienti oncologici. 2seventy bio si concentra sulla comprensione della risposta immunitaria del corpo umano alle cellule tumorali e sulla traduzione delle terapie cellulari in pratica.
2seventy bio (Nasdaq: TSVT) anunció su participación en la 22ª Conferencia Global de Salud de Morgan Stanley el 6 de septiembre de 2024 a las 12:20 p.m. ET en Nueva York. El equipo de gestión de la empresa participará en una charla informal, que será transmitida en vivo a través del sitio web de la empresa. Las reproducciones estarán disponibles durante 30 días después del evento.
2seventy bio es conocida por desarrollar la primera terapia CAR T aprobada por la FDA para el mieloma múltiple. El nombre de la empresa refleja su misión de trabajar a máxima velocidad (270 millas por hora) para dar más tiempo a los pacientes con cáncer. 2seventy bio se enfoca en comprender la respuesta inmune del cuerpo humano a las células tumorales y en traducir las terapias celulares en práctica.
2seventy bio (Nasdaq: TSVT)는 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 6일 정오 12:20 p.m. ET에 뉴욕에서 열립니다. 회사 경영진 팀은 실시간으로 방송될 대화에 참여할 것입니다. 이벤트 후에는 30일 동안 재생이 가능합니다.
2seventy bio는 다발성 골수종을 위한 FDA 승인 최초의 CAR T 세포 요법을 개발한 것으로 잘 알려져 있습니다. 회사 이름은 암 환자에게 더 많은 시간을 제공하기 위해 최대 속도(270마일/시)로 작업하겠다는 사명을 반영합니다. 2seventy bio는 인체의 면역 반응을 종양 세포에 이해하고 세포 요법을 실제로 전환하는 것에 중점을 두고 있습니다.
2seventy bio (Nasdaq: TSVT) a annoncé sa participation à la 22ème Conférence Globale sur la Santé de Morgan Stanley le 6 septembre 2024 à 12h20 ET à New York. L'équipe de direction de l'entreprise participera à une discussion informelle, qui sera diffusée en direct sur le site web de la société. Les rediffusions seront disponibles pendant 30 jours après l'événement.
2seventy bio est connue pour avoir développé la première thérapie CAR T approuvée par la FDA pour le myélome multiple. Le nom de l'entreprise reflète sa mission de travailler à la vitesse maximale (270 milles à l'heure) pour donner plus de temps aux patients atteints de cancer. 2seventy bio se concentre sur la compréhension de la réponse immunitaire du corps humain aux cellules tumorales et sur la mise en pratique des thérapies cellulaires.
2seventy bio (Nasdaq: TSVT) hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley am 6. September 2024 um 12:20 Uhr ET in New York angekündigt. Das Managementteam des Unternehmens wird an einem informellen Gespräch teilnehmen, das live übertragen wird auf der Unternehmenswebsite. Aufzeichnungen sind 30 Tage nach der Veranstaltung verfügbar.
2seventy bio ist bekannt dafür, die erste von der FDA genehmigte CAR-T-Zelltherapie gegen multiples Myelom entwickelt zu haben. Der Name des Unternehmens spiegelt seine Mission wider, mit maximaler Geschwindigkeit (270 Meilen pro Stunde) zu arbeiten, um Krebspatienten mehr Zeit zu geben. 2seventy bio konzentriert sich darauf, die Immunantwort des menschlichen Körpers auf Tumorzellen zu verstehen und Zelltherapien in die Praxis umzusetzen.
- None.
- None.
A live webcast of the fireside chat will be available via the Investors and Media section of the company’s website at https://ir.2seventybio.com. Replays will be archived on the 2seventy bio website for 30 days following the events.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829293557/en/
Investors:
Vicki Eatwell, CFO
vicki.eatwell@2seventybio.com
Media:
Morgan
Morgan.adams@2seventybio.com
Source: 2seventy bio
FAQ
When is 2seventy bio (TSVT) participating in the Morgan Stanley Global Healthcare Conference?
How can I watch 2seventy bio's (TSVT) fireside chat at the Morgan Stanley conference?
What is the significance of 2seventy bio's (TSVT) name?
What is 2seventy bio's (TSVT) main focus in cancer treatment?
